Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) Framework
Danielle Blunt(Royal Adelaide Hospital), Steven Lane(QIMR Berghofer Medical Research Institute), Sarah Finlayson(Heidelberg University), Hamish S. Scott(South Australia Pathology), Julia Dobbins(South Australia Pathology), David M. Ross(Flinders Medical Centre), Frank Lin(The University of Sydney), Anna Brown(South Australia Pathology), Gerlinda Amor(QIMR Berghofer Medical Research Institute), Helen Christensen(Cancer Research UK), Rosemary Harrup(University of Tasmania)
Cited by 0
Related Papers
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia
|Nature Genetics|2011|604
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
|Blood|2019|369
Delayed versus Immediate Cord Clamping in Preterm Infants
|New England Journal of Medicine|2017|304